'Not Approvable' Letter Thwarts Nanosphere's Hopes to Launch FDA-Approved Plavix PGx Test
June 22, 2011
'Not Approvable' Letter Thwarts Nanosphere's Hopes to Launch FDA-Approved Plavix PGx Test
"The issuance of the [FDA 'not approvable'] letter means that the company will encounter a delay in its plans to commercialize this product in the US," Nanosphere said in a statement.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Nanosphere Gets FDA OK for C. Difficile Test
December 10, 2012 / GenomeWeb Daily News - FDA Clears Nanosphere's CYP2C19 Test to Guide Therapeutic Strategy, Not Predict Response
November 14, 2012 / Pharmacogenomics Reporter - Nanosphere Gets FDA Clearance for Drug Metabolism Test
November 13, 2012 / GenomeWeb Daily News - Nanosphere Blood Infection Test Gets Moderate-Complexity Designation
November 1, 2012 / GenomeWeb Daily News - FDA Clears Nanosphere Test for Gram-positive Bacteria
June 27, 2012 / GenomeWeb Daily News